What Does the Published Research Say About KPV?

What This Article Covers

This article summarizes published research on KPV for technical review. It separates direct human evidence, review-level context, and animal or mechanistic work so the reader can see what has actually been tested before seeing the limitations.

• The evidence set comprises four human-study sources, one review, and several preclinical reports (cell, animal, and delivery/formulation). The human-study sources in this evidence set are not KPV intervention trials and do not establish KPV-specific clinical efficacy [pubmed:36175155; pubmed:35320643; pubmed:35830641; pubmed:40935835].
• The strongest conclusions should remain anchored to the specific populations/endpoints actually studied; do not generalize beyond those contexts. Parts of the evidence base are preclinical, limiting translational certainty.
• Dosing and systemic safety are not established by this evidence set and should not be inferred.

Evidence map (evidence set-level):

• Human-study sources: 4 (not KPV interventions)
• Review sources: 1 (contextual, not KPV-specific efficacy)
• Preclinical sources: multiple (in vitro, animal, delivery/formulation, structural/materials)

Bottom Line

• This evidence set does not provide KPV-specific human interventional outcome data. Available evidence is predominantly preclinical: cellular anti-inflammatory signaling findings, animal/colon-model barrier data using KPV-binding materials, transdermal and colon-targeted delivery studies, and peptide self-assembly/nanodrug work. These findings should not be presented as established human outcomes. The review material in the evidence set offers disease-context framing but is not evidence of KPV efficacy.

What Was Tested in Humans?

No controlled human intervention data were identified in the available evidence set used for this draft. That does not mean the compound has no research interest; it means human outcome claims should not be made from this article’s source base.

What Did Animal and Mechanistic Studies Show?

– [pubmed:40073467] Human keratinocyte model: KPV mitigated fine dust-induced apoptosis and inflammatory signaling by regulating oxidative stress and modulating MAPK/NF-κB pathways (in vitro/cellular). – [pubmed:22837805] Human bronchial epithelial cells: melanocortin-related peptides (including KPV-related mechanisms) inhibited inflammatory cues; implicated MC3R-related pathways (in vitro mechanistic study). A shared mechanistic theme across these in vitro studies is melanocortin-linked modulation of inflammatory signaling; this remains non-clinical.

• In vitro (cellular) findings

– [pubmed:35245681] A KPV-binding double-network hydrogel restored gut mucosal barrier function in a preclinical inflamed colon model (animal). No human outcomes were evaluated. – [pubmed:19909746] Colon-targeted drug-loaded nanoparticles within polysaccharide hydrogels reduced colitis severity in a mouse model (preclinical/delivery concept relevant to peptide interventions). Not KPV-specific efficacy.

• Animal models and tissue-level preclinical work

– [pubmed:28343991] Transdermal iontophoretic delivery of KPV across microporated human skin demonstrated permeation characteristics under iontophoresis (delivery/permeation study; not an efficacy trial and not evidence of systemic exposure). – [pubmed:39252648] KPV and rapamycin self-assembled into carrier-free nanodrugs evaluated for vascular calcification therapy in preclinical systems (preclinical/nanomaterials; not human outcomes).

• Delivery/formulation and nanomaterials

– [crossref:10.1211/0022357011776360] Conformational analysis of Ac-Lys-Pro-Val-NH2 (KPV motif) provides structural context (structural/biophysical; not efficacy). – [crossref:10.1021/acs.biomac.5c01800.s001] Self-assembly of Pro-Val-Pro-Val into nanoporous peptide frameworks (materials science context; not KPV-specific efficacy). – [crossref:10.1271/bbb.80473] Transepithelial transport characteristics of a non-KPV antihypertensive hexapeptide in Caco-2 monolayers (analog/transport context; not KPV-specific). – [pubchem:125672] Compound record for MSH(11–13) fragment (Lys-Pro-Val/KPV) (database record; structural/identifier context). – [crossref:10.1021/acs.jafc.3c02918.s001] Neuroprotection/gut microbiota study of a selenopeptide distinct from KPV (non-KPV; excluded from efficacy discussion).

• Structural/materials and related context

– [pubmed:37161053] Vimentin required for tumor progression/metastasis in a mouse NSCLC model (preclinical/oncology). This study is unrelated to KPV and should not be interpreted as informing KPV.

• Unrelated preclinical citation included in the evidence set

How the Evidence Fits Together

The practical reading for KPV is evidence hierarchy. Human studies, when present, carry the most weight, but only for the exact population, route, comparator, and endpoint studied. Reviews can help map the field, and animal or mechanistic studies can explain biological plausibility, but neither should be used to leap beyond the human evidence.

What Is Not Established

• Broad human efficacy for KPV is not established by this article.
• Animal, cellular, or review-level findings should not be converted into human-use claims.
• Dosing, administration, treatment, diagnostic, or veterinary-use guidance is outside the scope of KRL materials.

Research-Use Boundary

This article summarizes published research and regulatory-source discussion for technical review. It is not medical advice, not a dosing guide, and not a recommendation for human or veterinary use. KRL materials are sold for research use only and are not for diagnostic, therapeutic, or administration purposes.

Selected Sources

• Human-study/context citations: [pubmed:36175155]; [pubmed:35320643]; [pubmed:35830641]; [pubmed:40935835].
• Review (context only): [pubmed:28806188].
• Preclinical in vitro/cellular: [pubmed:40073467]; [pubmed:22837805].
• Preclinical animal/tissue-level: [pubmed:35245681]; [pubmed:19909746].
• Delivery/formulation/nanomaterials: [pubmed:28343991]; [pubmed:39252648].
• Structural/materials/records: [crossref:10.1211/0022357011776360]; [crossref:10.1021/acs.biomac.5c01800.s001]; [crossref:10.1271/bbb.80473]; [pubchem:125672]; [crossref:10.1021/acs.jafc.3c02918.s001] (non-KPV).

Related KRL Resources

• Research Compound Catalog
• Technical Products
• FAQ